Showing results (41-50 of 52) with videos related to
Sort By:
Pageof 6
Journal of Thrombosis and Haemostasis : JTH|September 13, 2024
The management of liver disease in people with congenital bleeding disorders: guidance from European Association for Haemophilia and Allied Disorders, European Haemophilia Consortium, ISTH, and World Federation of HemophiliaVincenzo La Mura, Massimo Colombo, Graham R Foster, et al.Haemophilia : the Official Journal of the World Federation of Hemophilia|July 26, 2021
Patient preferences and priorities for haemophilia gene therapy in the US: A discrete choice experimentMichelle Witkop, George Morgan, Jamie O'Hara, et al.Haemophilia : the Official Journal of the World Federation of Hemophilia|September 19, 2021
Evaluation of the sexual health in people living with hemophiliaFederico Germini, Chatree Chai-Adisaksopha, Drashti Pete, et al.European Journal of Haematology|June 9, 2016
The first Team Haemophilia Education meeting, 2015, Amsterdam, The NetherlandsErik Berntorp, Daniel Hart, Maria Elisa Mancuso, et al.Haemophilia : the Official Journal of the World Federation of Hemophilia|September 30, 2020
Telehealth for delivery of haemophilia comprehensive care during the COVID-19 pandemicMairead O'Donovan, Catherine Buckley, Julie Benson, et al.Haemophilia : the Official Journal of the World Federation of Hemophilia|July 29, 2025
Spinal Stenosis: An Emerging Complication of Ageing in People With HaemophiliaClaire Kelly, Mark McGowan, Niamh Larkin, et al.Research and Practice in Thrombosis and Haemostasis|May 24, 2021
Patient-relevant health outcomes for hemophilia care: Development of an international standard outcomes setErna C van Balen, Brian O'Mahony, Marjon H Cnossen, et al.The New England Journal of Medicine|March 16, 2022
Valoctocogene Roxaparvovec Gene Therapy for Hemophilia AMargareth C Ozelo, Johnny Mahlangu, K John Pasi, et al.Journal of Thrombosis and Haemostasis : JTH|September 7, 2023
Health-related quality of life following valoctocogene roxaparvovec gene therapy for severe hemophilia A in the phase 3 trial GENEr8-1Brian O'Mahony, Amy L Dunn, Andrew D Leavitt, et al.Journal of Thrombosis and Haemostasis : JTH|February 12, 2023
Heterogeneity in the half-life of factor VIII concentrate in patients with hemophilia A is due to variability in the clearance of endogenous von Willebrand factorEinas Elsheikh, Michelle Lavin, Lilian Antunes Heck, et al.Pageof 6